Б.Гантуяа
Loading...
Товч нэр
Б.Гантуяа
Бүтэн нэр
Болдбаатар Гантуяа
Латин нэр
Boldbaatar Gantuya
Албан тушаал
Ахлах багш
ORCID
Scopus Author ID
3 results
Now showing 1 - 3 of 3
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Utility of endoscopic pressure study integrated system for gastroesophageal reflux disease after endoscopic antireflux therapy(Wiley, 2025-06) ;Yamamoto, Kazuki ;Inoue, Haruhiro ;Tanaka, Ippei ;Ushikubo, KeiIwasaki, MiyukiOBJECTIVES: The endoscopic pressure study integrated system (EPSIS) measures intragastric pressure (IGP) during esophagogastroduodenoscopy. Previous research demonstrated that EPSIS correlates with the 24-h impedance-pH (MII-pH) test and shows lower maximum IGP (IGP-Max) and a flatter waveform gradient in gastroesophageal reflux disease (GERD) patients, attributed to lower esophageal sphincter dysfunction. Although endoscopic antireflux therapy (EARTh) is effective for GERD, the MII-pH monitoring, the gold standard for assessing treatment outcomes, requires hospitalization and can be a burden. EPSIS offers a noninvasive alternative for evaluating post-EARTh outcomes. This study aimed to assess EPSIS as an additional diagnostic tool in this context. METHODS: We conducted a retrospective analysis of GERD patients who underwent EARTh and were subsequently assessed using EPSIS within 6 months, from May 2018 to April 2024. Changes in IGP parameters, including IGP-Max and waveform gradient, were analyzed pre- and post-EARTh. Additionally, the study examined Hill's Classification following EARTh. RESULTS: Out of 39 patients assessed with EPSIS before and after EARTh, the average age was 55 years (standard deviation [SD] 16.7), with 64.1% male. Postoperative IGP-Max increased from 15.2 mmHg to 18.0 mmHg (P = 0.004), and the pressure gradient improved from 0.16 mmHg/s to 0.28 mmHg/s (P < 0.001). Hill's Classification improved significantly from a mean of 2.2 (SD 0.7) to 1.1 (SD 0.3) (P < 0.001). CONCLUSION: This study indicates that EPSIS is a reliable diagnostic tool for evaluating the effects of EARTh and holds potential as a supplementary tool for assessing GERD treatment outcomes.Scopus© Citations 6 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Wave height fluctuations in the waveforms of an endoscopic pressure study integrated system have the potential to predict acid reflux in gastroesophageal reflux disease (with video)(Wiley, 2025-09) ;Abiko, Satoshi ;Shimamura, Yuto ;Inoue, Haruhiro ;Saino, MasachikaUshikubo, KeiOBJECTIVES: The endoscopic pressure study integrated system (EPSIS) is a useful diagnostic tool for gastroesophageal reflux disease (GERD). Although wave height fluctuations have been observed in EPSIS waveforms, their clinical significance remains unclear. We hypothesized that the magnitude of these fluctuations may reflect lower esophageal sphincter functionality. This study aimed to evaluate the association between wave height fluctuations and objective acid reflux parameters. METHODS: A retrospective analysis was conducted on patients with GERD symptoms who underwent both EPSIS and 24-h multichannel intraluminal impedance-pH monitoring at a single tertiary center between June 2020 and December 2023. Abnormal acid reflux was defined as an acid exposure time (AET) ≥6.0%. Wave height was defined as the difference in intragastric pressure between the crest and trough of the EPSIS waveform. A diagnostic cut-off value for wave height was determined, and factors associated with elevated wave height were analyzed. RESULTS: A total of 129 patients were included, of whom 29 (22.5%) had abnormal acid reflux. The median wave height was 2.5 mmHg. Patients with AET ≥6% had significantly higher wave heights than those with AET <6% (P = 0.0141). A wave height of 3.1 mmHg demonstrated optimal diagnostic performance for predicting abnormal AET. Multivariate analysis revealed that abnormal AET (odds ratio 3.43, 95% confidence interval 1.39-8.44, P = 0.0074) was independently associated with wave heights ≥3.1 mmHg. CONCLUSIONS: Wave height fluctuations in EPSIS waveforms may reflect lower esophageal sphincter dysfunction and serve as a novel predictor of pathological acid reflux in patients with GERD.Scopus© Citations 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, A pilot study on anti-reflux mucoplasty with valve as novel endoscopic therapy for gastroesophageal reflux disease(Wiley, 2026-04) ;Yamamoto, Kazuki ;Inoue, Haruhiro ;Tanaka, Ippei ;Miyake, ReiSaino, MasachikaBACKGROUND AND AIMS: Endoscopic anti-reflux therapies like anti-reflux mucosectomy (ARMS) and anti-reflux mucosal ablation have shown efficacy for gastroesophageal reflux disease (GERD) in systematic reviews and meta-analyses. Anti-reflux mucoplasty (ARM-P), a refinement of ARMS, incorporates immediate closure of the resection site to reduce complications. Recently, anti-reflux mucosal valvuloplasty (ARMV), which employs endoscopic submucosal dissection to create a mucosal valve, was introduced but retains ARMS's limitations, requiring extensive incisions (three-quarters to four-fifths circumference). To address these challenges, we developed anti-reflux mucoplasty with valve (ARM-P/V), integrating ARMV's valvuloplasty with ARM-P's closure technique to improve safety and reduce complications. This pilot study evaluates the safety, feasibility, and efficacy of ARM-P/V. METHODS: This retrospective study reviewed data from patients undergoing ARM-P/V for proton pump inhibitor (PPI)-refractory or PPI-dependent GERD at Showa University Koto Toyosu Hospital, Tokyo, from April to August 2024. Symptom severity and quality of life were assessed using validated questionnaires (GERD-Health Related Quality of Life Questionnaire [GERD-HRQL], GERD Questionnaire [GerdQ], and Frequency Scale for the Symptoms of GERD [FSSG]), comparing pre- and post-treatment scores. PPI discontinuation rates were also analyzed. RESULTS: Eighteen patients (mean age 55.4 years) underwent ARM-P/V. Within 3 months, 72.2% (13/18) reduced or discontinued PPI use. GERD-HRQL scores improved from 20.3 to 10.9 (p = 0.004), GerdQ from 10.4 to 6.9 (p < 0.001), and FSSG from 24.0 to 13.2 (p < 0.001). No severe complications (Clavien-Dindo Grade ≥3), delayed bleeding or dysphagia requiring balloon dilation were reported. CONCLUSIONS: ARM-P/V demonstrates safety, technical feasibility, and short-term efficacy in GERD treatment. As a refinement of ARMV, it offers a promising alternative to current techniques.Scopus© Citations 5
